UNAIDS News and Research

RSS

Action needed to reverse a growing HIV epidemic in Asia

Nationwide programs to increase condom use in commercial sex, help drug injectors to use clean needles and cut risky sex between men are needed to reverse a growing HIV epidemic in Asia, according to leading scientists.

11 Jul 2004

Women now account for half of the people living with HIV worldwide

Women now account for half of the people living with HIV worldwide and represent one of the fastest growing populations affected by the disease.

7 Jul 2004

2004 UNAIDS Report - last year 5 million people became infected with HIV

UNAIDS has warned that the number of people living with HIV, the virus that causes AIDS, has risen in every region of the world and last year 5 million people became newly infected with HIV - more people than any previous year.

6 Jul 2004

Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment

Today Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment, accounting for more than half of all people on antiretrovirals in developing countries

25 Jun 2004

WHO removes two antiretroviral products from the WHO List of prequalified products

The World Health Organization (WHO) removed two antiretroviral products from the WHO List of prequalified products

20 Jun 2004

Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment

Today Latin America and the Caribbean lead the developing world in providing HIV/AIDS treatment, accounting for more than half of all people on antiretrovirals in developing countries, according to the Pan American Health Organization (PAHO).

15 Jun 2004

WHO welcomes G8 endorsement of the Global HIV Vaccine Enterprise

The World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) today welcomed the G8's endorsement of the Global HIV Vaccine Enterprise, a virtual consortium proposed by an international group of scientists that is being established to accelerate HIV vaccine development.

11 Jun 2004

Plans for once-daily, fixed-dose combination of three anti-HIV drugs

Bristol-Myers Squibb Company, Gilead Sciences, Inc. and Merck & Co., Inc. have announced that they are in discussions on the development of a once-daily, fixed-dose combination of three anti-HIV drugs and are also considering certain co-packaging options for the individual products.

16 May 2004

Critical moment in the history of HIV/AIDS, more money, more political will, more deaths

This is a critical moment in the history of HIV/AIDS. There is more money, more political will and more attention being paid to this killer disease than ever before. And yet, more people than ever are dying of AIDS and becoming infected with HIV.

11 May 2004

New centre for AIDS research opens in Southampton UK

International experts on HIV/AIDS were in Southampton today (Thursday 15 April) to mark the official opening of a new Centre for AIDS Research at the city's University.

16 Apr 2004

African summit on treatment of AIDS, tuberculosis and malaria

In Gaborone, Botswana, government officials and representatives of drug regulatory agencies from 23 nations, the research-based and generic pharmaceutical industries, public health leaders, health care providers, advocacy groups (including persons living with HIV/AIDS), academia and members of non-governmental organizations held discussions from March 29-31 on the scientific and technical principles for fixed-dose combination drug products (FDCs) for use in the treatment of AIDS, tuberculosis and malaria, the most serious infectious disease threats facing the world today.

8 Apr 2004

IPM takes over Microbicide development to protect against sexual transmission of HIV

International Partnership for Microbicides (IPM) today announced that it has reached a farsighted agreement with Tibotec Pharmaceuticals Ltd, a subsidiary of Johnson & Johnson. The aim is to develop the promising compound TMC120 as a safe and effective microbicide to help protect women from infection with HIV. This agreement marks the first collaboration in the microbicide field between a major healthcare company and a public-private partnership such as IPM.

29 Mar 2004